# Novartis: ianalumab disease activity in Sjögren's disease kept improving to week 108 of monthly dosing

- Published: 2026-11-10 22:20 UTC
- Section: Life & Health › Medicine
- Tags: Novartis ianalumab, Sjögren's disease, autoimmune disease, B-cell antibody, monoclonal antibody, week 108 results, American College of Rheumatology, FDA decision
- URL: https://realtech.media/news/rt-eb2f6a5d083cd7db0c147e3f_novartis_ianalumab_disease/

**Ianalumab, an anti-B-cell antibody under regulatory review, showed further improvement in Sjögren's disease activity over two years of monthly dosing, according to Novartis.**

![Novartis: ianalumab disease activity in Sjögren's disease kept improving to week 108 of monthly dosing](https://realtech.media/media/2026/11/5eabf64bb34988bb.jpg)
*Brigida Anna Maiorano,Martina Catalano,Evaristo Maiello,Giandomenico Roviello, Wikimedia Commons, CC BY 4.0*

Novartis reported that in patients with Sjögren's disease who received ianalumab monthly for two years, disease activity continued to improve through week 108, ad-hoc-news.de reports [1]. The company presented the results on Tuesday in a poster session at the annual congress of the American College of Rheumatology [1].

Sjögren's disease is an autoimmune disorder that mainly affects the glands and causes severe dryness of the eyes and mouth. It can also damage other organs.

Ianalumab is a monoclonal antibody that targets B cells, which play an important role in this autoimmune disease [1]. The drug candidate is under regulatory review in several countries. In the US, a decision by the FDA is expected before the end of the current year [1].

## Sources

1. [ad-hoc-news.de](https://www.ad-hoc-news.de/boerse/news/corporate-news/novartis-ianalumab-zeigt-weitere-verbesserungen-nach-zwei-jahren/70488275)

---

Source: RealTech, realtech.media — https://realtech.media/news/rt-eb2f6a5d083cd7db0c147e3f_novartis_ianalumab_disease/